Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Long term treatment of pulmonary embolism (PE) with low molecular weight heparin (LMWH) (tinzaparin). Preliminary results Source: Eur Respir J 2007; 30: Suppl. 51, 80s Year: 2007
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001
Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001
Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
Successful heparin desensitization after anaphylactic shock due to low molecular weight heparin Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005
Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004
Comparison of long –term outcomes of 50 mg rt-PA and 100 mg rt-PA in the management of acute pulmonary embolism Source: International Congress 2016 – Acute pulmonary embolism Year: 2016
Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 684s Year: 2004
Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE Source: Eur Respir J 2005; 26: Suppl. 49, 699s Year: 2005
Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005
The treatment of sub massive pulmonary embolism: Thrombolytic or heparin? Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012
Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007
Interventional treatment of pulmonary embolism: catheter-delivered local thrombolysis versus reduced-dose systemic thrombolysis Source: Virtual Congress 2021 – Pulmonary embolism: controversies in management Year: 2021
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Ten years experience of use of intrapleural streptokinase (IPSK) for empyema Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001